Summary
BeiGene, Ltd. (ONC) filed an 8-K on November 4, 2021, to report its financial results for the third quarter and first nine months of 2021. While the filing itself is brief, it references a press release containing detailed financial information and operational updates. Investors should refer to the full press release (Exhibit 99.1) for specifics on revenue, expenses, net loss, and cash flow. In addition to financial performance, the 8-K highlights significant clinical progress, particularly in the hematology division. The company announced upcoming presentations of clinical and real-world data for its BRUKINSA® (zanubrutinib) program at the 63rd American Society of Hematology (ASH) Annual Meeting. This includes crucial Phase 3 SEQUOIA trial data comparing BRUKINSA® to a standard treatment for chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), a key development for the company's oncology pipeline.
Key Highlights
- 1BeiGene reported financial results for the third quarter and nine months ended September 30, 2021.
- 2The company will present clinical results and real-world data for its hematology program at the 63rd ASH Annual Meeting (December 11-14, 2021).
- 3Key presentations will include Phase 3 SEQUOIA trial data for BRUKINSA® (zanubrutinib) in treatment-naïve Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL).
- 4The SEQUOIA trial compares BRUKINSA® against the combination of bendamustine and rituximab (B+R).
- 5The ASH meeting will be conducted in a hybrid format (in-person in Atlanta, GA, and virtually).
- 6The filing incorporates by reference two press releases containing detailed financial results and business updates.